General Information of Drug (ID: DMJGYPK)

Drug Name
AZD9056 Drug Info
Synonyms
AZD-9056; AZD9056; 345304-65-6; UNII-F13K378W4L; N-(1-adamantylmethyl)-2-chloro-5-[3-(3-hydroxypropylamino)propyl]benzamide; F13K378W4L; AZD 9056; GTPL7826; SCHEMBL4126642; CHEMBL3545108; HSQAARMBHJCUOK-UHFFFAOYSA-N; MolPort-044-723-510; KS-000000WO; BCP25185; ZINC34356159; AKOS030228502; DB12594; Benzamide, 2-chloro-5-(3-((3-hydroxypropyl)amino)propyl)-N-(tricyclo(3.3.1.13,7)dec-1-ylmethyl)-; 2-Chloro-5-[3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide
Indication
Disease Entry ICD 11 Status REF
Chronic obstructive pulmonary disease CA22 Phase 2 [1]
Cross-matching ID
PubChem CID
10161381
CAS Number
CAS 345304-65-6
TTD Drug ID
DMJGYPK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug(s) Targeting P2X purinoceptor 7 (P2RX7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CE-224535 DMFCLT6 Arthralgia ME82 Phase 2/3 [3]
LY3857210 DMZO2V2 Pain MG30-MG3Z Phase 2 [4]
BIL010t DMV1EA9 Alzheimer disease 8A20 Phase 1/2 [5]
EVT 401 DMOG8IE Rheumatoid arthritis FA20 Phase 1 [6]
SGM-1019 DMDAHEL Inflammatory bowel disease DD72 Phase 1 [7]
GSK1482160 DMWDQOV Pain MG30-MG3Z Phase 1 [8]
JNJ-55308942 DM0QZJX Anhedonia MB24.2 Phase 1 [5]
JNJ-54175446 DMQ5ZVK Major depressive disorder 6A70.3 Phase 1 [9]
JNJ-479655 DMDU6GN Alzheimer disease 8A20 Clinical trial [10]
Quinoline derivative 12 DM9FXE7 N. A. N. A. Patented [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
P2X purinoceptor 7 (P2RX7) TT473XN P2RX7_HUMAN Antagonist [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7826).
2 Clinical pipeline report, company report or official report of AstraZeneca (2009).
3 Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012 Apr;39(4):720-7.
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
5 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
6 Molecular and functional properties of P2X receptors ecent progress and persisting challenges. Purinergic Signal. 2012 September; 8(3): 375-417.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br J Pharmacol. 2013 Oct;170(3):624-40.
11 P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267.